Kathmandu- With generic versions of weight-loss drugs rapidly spreading in India, the Ministry of Health has issued a strong warning about potential misuse and associated health risks. The ministry emphasized that unsupervised use without a doctor’s prescription could lead to serious side effects, and has strengthened monitoring and enforcement measures.
The patent for the active ingredient semaglutide, used in drugs like Ozempic and Wegovy, expired in March 2026, leading to a surge in generic production in India. These GLP-1 class drugs are effective for obesity as they regulate blood glucose levels and appetite hormones. However, the health ministry cautioned that unsupervised use could pose significant health risks.
With multiple generic variants now available, the drugs are increasingly being sold through retail pharmacies, online platforms, wholesalers, and wellness clinics, raising concerns of uncontrolled distribution. India’s drug regulatory authority has tightened inspections and prohibited misleading marketing or promotion of unsafe usage.
Simon Barker, President of the World Obesity Federation, noted that obesity is a complex and chronic condition, and drugs alone cannot solve it. Healthy lifestyle changes and preventive measures are equally important.
The market for weight-loss drugs in India has grown rapidly over the past five years. By 2026, sales reached $153 million and are projected to surpass $500 million by 2030. According to government statistics, 24% of women and 23% of men in India are overweight or obese. Previously, these drugs cost between INR 15,000–22,000 per month, limiting their use, but generic semaglutide now costs between INR 1,300–4,200, expanding accessibility.
